Jake is the Chief Scientific Officer and one of the founding scientists of Volition. He is an experienced scientist with expertise in research and development and in the management of early-stage biotechnical companies, including the manufacturing of biotechnology products and the establishment of manufacturing operations. Jake is the co-inventor and author of the patents surrounding Volition’s Nucleosomics™ technology.
Jake received both his BSc in Biology and Chemistry, and PhD in Physical Chemistry from King’s College London. In addition, he received his MSc in Chemical Pathology from St Thomas’ Hospital Medical School, and his MBA from Imperial College Management School.
“Current cancer diagnosis involves expensive, unpleasant and, often, invasive testing. Using our Nu.Q technology we aim to make cancer diagnosis as accessible as cholesterol or pregnancy testing”